

## CURRICULUM VITAE

Name Robert Castleman Green, MD, MPH

Address Genetics Program and Alzheimer's Disease Center  
Boston University (BU) School of Medicine, 715 Albany Street, L-320, Boston, MA 02118  
tel: (617) 638-5362, email: [rcgreen@bu.edu](mailto:rcgreen@bu.edu), web: [www.bu.edu/alzresearch](http://www.bu.edu/alzresearch)

### Education

1976 BA (Biology and English) Amherst College, Amherst, Massachusetts  
1980 MD University of Virginia Medical School, Charlottesville, Virginia  
2000 MPH (Epidemiology) Emory University School of Public Health, Atlanta, Georgia

### Post-Doctoral Training

1980-1981 Intern in Medicine, Rhode Island Hospital, Providence, Rhode Island  
1981-1982 Public Health Training and Service in rural Nepal via Johns Hopkins School of Public Health.  
1982-1985 Resident and Chief Resident in Neurology, Longwood Neurology Training Program  
Harvard Medical School, Brigham and Women's Hospital and Beth Israel Hospital  
1985-1986 Fellow, Division of Neuroscience and Behavioral Neurology, Beth Israel Hospital and  
Harvard Medical School (sponsor: M-M. Mesulam)  
1986-1987 Fellow in Pediatric and Adult Epilepsy/EEG, The Children's Hospital  
Harvard Medical School (sponsors: C. Lombroso, G. Erba, R. Sidman)

### Academic Appointments

1985-1987 Research Fellow in Neurology, Harvard Medical School  
1987-1988 Instructor in Neurology, Harvard Medical School  
1988-1994 Assistant Professor of Neurology, Emory University School of Medicine  
1994-1996 Associate Professor of Neurology, Emory University School of Medicine  
Assistant Professor in Psychiatry and Behavioral Sciences and Center for Geriatrics  
1996-1999 Visiting Professor, College of Health and Human Sciences, Georgia State University  
1998-2000 Clinical Associate Professor of Medicine, Morehouse School of Medicine  
1999-2003 Associate Professor of Neurology, BU School of Medicine (BUSM)  
2003- Professor of Neurology, Medicine (Genetics), and Graduate Medical Sciences, BUSM  
2003- Professor of Epidemiology, BU School of Public Health

### Hospital, Clinic and Administrative Appointments

1982-1987 Behavioral Neurology Unit, Beth Israel Hospital, Boston  
1983-1987 Staff, Boston State Psychiatric Hospital, Dorchester, MA  
1983-1988 Consultant in Behavioral Neurology, Ladd Center for the Retarded, North Kingston, RI  
1986-1988 Learning Disabilities Program & Cerebral Palsy Clinic, The Children's Hospital, Boston  
1988-1991 Associate Chief of Neurology, Wesley Woods Geriatric Center, Atlanta, GA  
1991-1994 Chief of Neurology, Wesley Woods Geriatric Center, Atlanta, GA  
1988-1996 Neurologist, The Emory Clinic and Emory University Hospital, Atlanta, GA  
Director, Emory Neurobehavioral Program & Memory Assessment Clinic  
1996-1999 Director, Memory Assessment Clinic and Alzheimer's Disease Program  
Georgia State University, Co-Director, Georgia Alzheimer's Disease Consortium  
1999- Neurologist and Co-Director, Memory Assessment Clinics, Boston Medical Center  
2001- Assoc Director & Clinical Core Leader, NIH Alzheimer's Disease Core Center, BUSM  
2004- Director, Alzheimer's Disease Clinical and Research Program, Neurology Department, BUSM

### Research Interests

- 1987-1990 Histopathology of Temporal Lobe Epilepsy
- 1988- Behavioral Phenomenology and Clinical Trials for Dementing Disorders
- 1995- Genetic Epidemiology, Risk Estimation and Prevention of Alzheimer's Disease
- 2000- Genetic Testing, Risk Assessment and Risk Communication

### Awards and Honors

- 1980 Society of Fellows, University of Virginia School of Medicine
- 1985 William B. Lennox Postdoctoral Research Fellowship
- 1986 Biomedical Research Support Award, Beth Israel Hospital
- 1986 Wilder Penfield Clinical Research Fellowship
- 1987 The Children's Hospital United CP Fellowship Award and Farley Award
- 1994 Cited in Woodward & White's "Best Doctors in America" for Behavioral Neurology
- 1998 National Finalist, Robert Wood Johnson Community Health Leadership Award
- 2003 Named as Fellow of the American Neuropsychiatric Association

### Licensures and Certifications

- Licensed in Massachusetts (1982)
- Board Certified in Neurology (1991)

### Reviewer

- Editorial Board: Journal of Neuropsychiatry and Clinical Neurosciences (1995- )  
Medscape Neurology (online medical publishing) (2001- )
- Journal reviewer: New England Journal of Medicine, JAMA, Neurology, Archives of Neurology, Alzheimer's Disease and Related Disorders, Gerontologist, Psychology and Aging, American College of Physicians Journal Club, Alzheimer's Disease, Journal of Geriatric Psychiatry and Neurology, Alzheimer's & Dementia
- Grant Reviewer: Veteran's Affairs Coop Studies in Health Services Review Committee (1996-1999)  
National Alzheimer's Association Grant Reviewer (1998-present)  
National Institute on Aging Special Emphasis Panel (2003-present)
- Data Monitoring: Cooperative Studies Program Data Monitoring Board CS #029 (1997-1999)  
Data Safety and Monitoring Board, Curcumin Phase II Trial (2004-present)

### Professional Societies and National Positions

- American Academy of Neurology (Chair, Behavioral Neurology Section 1999-2001; Geschwind Award Committee, 1993-1998)
- Society for Behavioral and Cognitive Neurology (National President 1999-2001)
- American Neuropsychiatric Association  
(Education Committee, 1993-1995; Chair, Scientific Program Committee, 1995-1999)
- Examiner, American Board of Psychiatry and Neurology (1999-2000)
- Chair, Data and Publications Committee, Executive Committee Member, ADNI (2005-present)

### Advisory Positions

1993-1995 Consultant to Aging Branch, Center for Chronic Disease, CDC, Atlanta, Georgia  
1995 Editing Dementia sections: Diagnosics & Statistical Manual of Mental Disorders - IV  
2001- Neurology Faculty and Editorial Board for Medscape.com (on-line medical publishing)  
2001-2003 Invited Participant in planning meetings on the future of the Human Genome Project  
2002-2005 Advisor (compensated): Forest, Pfizer, Beyond Genomics  
2005- Advisor (uncompensated): Myriad, SmartGenetics, DNADirect, 23andMe, Navigenics

#### Emory University School of Medicine Service and Teaching (1988-1996)

- Established and directed Emory Neurobehavioral Program. Recruited and directed clinical and support staffing of this program such that by 1996 it included 6 faculty, 2 postdoctoral fellows, 3 research nurses, 6 clinical/research technicians and 3 support staff.
- Established first geriatric neurology resident, psychiatry resident and neurology faculty ward rotations at Wesley Woods Geriatric Hospital.
- Appointed by the department chair to the Neurology Clinical Operations Committee and Development/Fund Raising Committee.
- Appointed by the Dean to the Emory University Human Investigations Committee (IRB).
- Established, funded and supervised a Neurobehavioral Research Fellowship.

#### Boston University Service and Teaching (1999- present)

- Established and directed/now co-directs (with Robert Stern, PhD) the BU Alzheimer's Disease Clinical and Research Program. Recruited and directed clinical and support staffing of this program such that at present it includes 4 faculty, 2 postdoctoral fellows, 4 research nurses, 4 project coordinators, 7 clinical/research technicians and 4 administrative staff.
- Appointed by department chair to lead the Neurology "Clinical Services" committee restructuring ward experience for neurology residents.
- Appointed by department chair to Promotions Committee.
- Invited Member of Mentor Panel, NIH-funded Research Career Development Program through the Women's Center of Excellence
- Invited Member of Steering Committee, Hartford/Rand-funded BU Aging Research Center.
- Established and coordinates the weekly Alzheimer's Disease Research Seminar Series.
- Appointed by Dean to BU Medical School Promotions Committee.

#### Supervision of Trainees

1989-1991 Steven M. Hersch, M.D., Ph.D., Neurobehavioral Research Fellow  
funded by HDSA and NINDS, currently faculty at Harvard  
1991-1992 Alex P. Auchus, M.D., Neurobehavioral Research Fellow  
1992-1993 Raymond Capps, M.D., Neurobehavioral Research Fellow  
1993 Gustavo Rodrigo, M.D., Fullbright Foreign Scholar  
fellowship funded through the Council for International Exchange of Scholars  
1993 Richard D. Tucker, Ph.D. Visiting Professor for 3 months  
currently Professor of Psychology and Director, UCF Initiative on Aging and Longevity  
1993-1994 David Olson, M.D., Neurobehavioral Research Fellow, funded through NIA  
1993-2001 Thesis or Project Advisor to 7 Masters level or PhD candidates (Emory, Georgia Tech)  
1999-2001 Primary Advisor to Yvonne Hipps, Ph.D. , awarded NIA Minority Supplement Training Grant  
currently Assistant Professor at Morehouse School of Medicine

- 2002 Research master's thesis advisor to David Tsai, M.D., geriatric fellow
- 2002 Aisha Traish, winner Medical Student AAN Summer Research Scholarship for work with us
- 2002 Dexter Wong, winner Hartford AFAR Summer Research Award for work with us
- 2003 Research master's thesis advisor to Jaza Marina, M.D. and Serena Chao, M.D., geriatric fellows
- 2003- Primary Advisor to Abimbola Akomolafe, M.D., awarded an NIA Minority Supplement Training Grant, currently Associate Professor at Morehouse School of Medicine
- 2004-2005 Thesis Advisor to Anna Odendahl, MD, graduate student from Germany
- 2004-2005 Advisor to Dapo Akinleye, BU graduate student, awarded NIA Minority Supplement Training Grant, currently PhD candidate in epidemiology
- 2004- Supervisor to rotating graduate students from Netherlands
- 2006- Advisor to Anil Nair, MD, Assistant Professor of Neurology at BU School of Medicine
- 2006-2007 Supervisor to Winston Chung, medical student research fellow
- 2007- Advisor to Ilona Kopits, MD, Geriatric Fellow at BU School of Medicine

#### Major Media Appearances in the last 5 Years

- 2002-present Appearances and quotations on local and national television, radio and print media
- 2002, 2004 Appearances in featured stories on NBC and CBS Nightly News
- 2007 Co-Host in documentary for PBS series 'Healthy Body, Healthy Mind'
- 2006-2008 Work featured in New York Times, Wall Street Journal and USA Today
- 2008 Featured participant in HBO documentary on Alzheimer's Disease

#### Other Interests

##### *Singing*

- Atlanta Symphony Orchestra Chorus (1995-1999), conducted by the late Robert Shaw
- Performed at the Opening Ceremonies of the Olympics Games in Atlanta (1996)
- Grammy Awards: Best Choral Recordings (1997, 1998) and Best Classical Album (1998)
- Tanglewood Festival Chorus (1999-2001), conducted by John Oliver
- Acapella Singing Performances (2005 - present)

##### *Scuba Diving*

##### *Mountain Biking*

Selected National and International Presentations since 2000

- 1995-2007 Invited Speaker, Renaissance Weekend (with the President of the United States 1995-1999)  
Hilton Head, South Carolina *Alzheimer's Disease, Predictive Genetic Testing*
- 2001 Invited Speaker, Decade of ELSI Research Conference, National Human Genome Institute,  
Bethesda, MD. *The REVEAL Study: Developing Cumulative Risk Profiles to Provide  
Susceptibility Genotyping, Risk Assessment and Counseling for Alzheimer Disease*
- 2001 Invited Participant, NHGRI-sponsored conference. "The Future of Genomics"  
Warrenton, Virginia
- 2002 Invited Participant, NIA Workshop on the Genetics of Alzheimer's Disease.  
Bethesda, MD
- 2002 Invited Participant, NHGRI Workshop on "Genome to Health".  
Bethesda, MD
- 2003-2005 Course Director and Invited Speaker, Boston Alzheimer's Symposium
- 2005 Invited Speaker, NIA Conference on Aging, Genetics and Technology at Boston College  
Boston, MA  
*Implication of Genetic Testing for Alzheimer's Disease: The REVEAL Study*
- 2005 Invited Speaker, Medicine Pan-Hellenic Alzheimer's Disease Conference  
Thessaloniki, Greece. *Genetic Risk Assessment: The REVEAL Study*
- 2005 Invited Speaker, Annual Meeting of the American Society of Law, Medicine & Ethics  
Boston, MA  
*Fetal and Early Screening for Late Onset Disorders*
- 2005 Invited Speaker, National Coalition Health Care Professionals for Education in Genetics  
Baltimore, MD  
*Clinical Implications of Neuropsychiatric Genetics*
- 2005 Invited Speaker, World Congress on Psychiatric Genetics, Boston  
*Genetic Risk Assessment*
- 2005 Invited Speaker, Graylyn Conference on Women's Cognitive Health  
Winston-Salem, NC  
*Susceptibility Testing and Genetic Risk Assessment*
- 2006 Invited Participant, National Genetic Policy Summit on Genetic Testing  
Washington, DC
- 2007 Invited to brief Congress on Alzheimer's Disease and Genetics

- Washington, DC
- 2007 Boston Museum of Science Featured Speaker  
Boston, MA
- 2007-2008 Invited Speaker, Alzheimer's Association Research Roundtable  
Washington, DC  
*Risk Assessment for Alzheimer's Disease (2007)*  
*Optimal Clinical Trial Design (2008)*
- 2008 Speaker and Panelist, National Press Club Presentation on Personal Genomics  
Washington, DC  
*The Impact of Disclosure in Personal Genomics*
- 2008 Keynote Speaker, Mountain States Genetics Foundation  
Denver, CO  
*Presymptomatic Testing for Neurological Disorders*
- 2008 Invited Speaker, National Human Genome Research Institute  
Bethesda, MD  
*Health benefits of genomics: Developing an agenda for social and behavioral research*
- 2008 Presidential Symposium Speaker, American Psychological Association  
Boston, MA  
*Challenges of Aging: Lessons from Medicine, Psychology and Law*
- 2008 Speaker and Panelist, Social Issues Session  
American Society for Human Genetics  
Philadelphia, PA  
*Impact and Utility of Personalized Genomic Information*

Current Grant Funding

- 1999-2009 PI (15% support)  
*Genetic Risk Assessment and Counseling for Alzheimer's Disease*  
\$1,641,238. National Human Genome Research Institute, RO1-HG/AG 02213
- 2006-2011 PI (50% support)  
*Characterizing and Communicating Genetic Risk for Alzheimer's Disease*  
\$846,322. (direct) National Institute on Aging, K24-AG027841
- 2002-2009 Co-PI (20% support)  
*Multi-Institutional Research in Alzheimer's Disease Epidemiology*  
\$9,875,930 (direct) National Institute on Aging, RO1-AG09029 (L. Farrer, PI)
- 1999-2011 Associate Director and Clinical Core Director (15% support)  
*Boston University Alzheimer's Disease Center*  
\$4,072,994 (direct) National Institute on Aging, P30-AG13846 (N. Kowall, PI)
- 2001-2011 Co-I, National Steering Committee and BU Site Director  
*Alzheimer's Disease Cooperative Study*  
National Institute on Aging, U01-AG10483 (P. Aisen, PI)  
(3 active protocols at Boston University)
- 2001-2008 Co-I, Executive Committee and Project PI (5% support)  
*Population-Based, Multidisciplinary Study of Centenarians*  
*PI of Project 2: Neuropathology of Centenarians*  
\$7,499,999. National Institute on Aging P01-AG 17553 (L. Poon, PI)
- 2005-2010 Co-I  
*Epidemiology of Dementia in the Framingham Study* (5% support)  
\$4,047,068. National Institute on Aging RO1-AG 08122 (P. Wolf, PI)
- 2004-2009 Co-I, National Steering Committee and BU Site Director  
*Alzheimer's Disease Neuroimaging Initiative*  
National Institute on Aging (M. Weiner, PI) U01-AG 24904
- 2008-2011 Site PI  
*Communicating Diagnostic and Risk Information in Mild Cognitive Impairment National Alzheimer's Association* (5% support)  
Investigator-Initiated Research Grants Program (J.S. Roberts, PI)
- 2001-2012 Co-I and Mentor  
*Neurobiology and Neuropsychology of Aging Training Grant*  
\$770,786. National Institute on Aging T32-AG 00277 (M. Moss, PI)
- 2008-2013 Co-I

- Hypothyroidism: Mood, Cognition and the Effect of L-Thyroxine Treatment*  
\$ 2,521,671. National Institute of Mental Health R01-MH080295 (R. Stern, PI)
- 2008-2011 Co-I  
Assessment of Driving Safety in Aging, MCI and Alzheimer's Disease  
\$240,000. Alzheimer's Association Investigator-Initiated Research Grant (R. Stern, PI)
- 2002-2008 Consultant  
*Cache County Study on Memory and Aging*  
National Institute on Aging RO1-AG 11380 (K. Welsh-Bohmer, PI)
- 2002-2008 Consultant  
*Progression of Dementia: A Population Study*  
National Institute on Aging, AG/MH 21136 (J. Tschanz, PI)
- 2005-2010 Consultant  
*Genetics of Alzheimer's Disease Among Israeli Arabs*  
National Institute on Aging, AG017173 (R. Friedland, PI)
- 2007-2012 Consultant  
*Wisconsin Registry of Alzheimer's Disease*  
National Institute on Aging (M. Sager, PI)

Completed Grant Funding (Federal)

- 1990-1993 Co-PI (20% support)  
*Reducing Frailty in Elders*  
\$671,596. National Institute on Aging, UO1-AG09124 (Steve Wolf, PI)
- 1991-1993 PI (15% support)  
*Computer-Based Cognitive Screening*  
\$62,750. Aging Branch, Centers for Disease Control
- 1991-1994 Co-PI (15% support)  
*Special Care Units for Alzheimer's Disease*  
\$1,053,504. National Institute on Aging, UO1-AG10306 (N. Kutner, PI)
- 1991-1995 PI-Clinical Core (20% support)  
*Emory Alzheimer's Disease Core Center*  
\$3,342,266. National Institute on Aging, P30-AG10130 (S. Mirra, overall PI)
- 1991-1992 Co-I (5% support)  
*Head Trauma in the Elderly*  
\$49,997. National Inst of Disability/Rehabilitation Research, H133000097 (F. Goldstein, PI)
- 1992-1995 PI (15% support)

- Management Interventions in Alzheimer's Disease*  
\$348,028. National Institute on Aging, RO1-AG 11503
- 1993-1995 Site Director (Emory)  
*Alzheimer's Disease Cooperative Study*  
\$85,000. National Institute on Aging (Leon Thal, PI)
- 1993-1996 Co-I (5% support)  
*Traumatic Brain Injury in Older Adults*  
\$374,934. Natl Inst on Disability/Rehabilitation Research, H133G30051 (F. Goldstein, PI)
- 1993-1995 Site Director (Emory)  
*Multi-Institutional Research in Alzheimer's Disease Epidemiology*  
\$120,000. National Institute on Aging, RO1-AG09029 (L Farrer, PI)
- 1993-1995 Co-I (5-20% support)  
*A Study of the Health Effects of Exposure to Elemental Mercury*  
\$222,534. National Institute for Occupational Safety and Health (R. Letz, PI)
- 1994-1995 Co-I  
*Activation of Cerebral Blood Flow During Explicit Rehearsal in Alzheimer's Disease*  
\$20,000. National Institute on Aging (J. Woodard, PI)
- 1996-2001 Co-I  
*Functional Neuroanatomy of Memory in Alzheimer's Disease*  
\$528,542. National Institute on Aging R29-AG 18912 (J. Woodard, PI)
- 1996-2001 Co-PI (25% support)  
*Genetic Epidemiological Studies of Alzheimer Disease in African Americans*  
\$1,263,015. National Institute on Aging, RO1-AG09029-S (L. Farrer, PI)
- 1999-2002 Co-I  
*Aging, Metamemory, and Strategy Use During Learning*  
\$1,148,059. National Institute on Aging, RO1-AG 13148-04A1 (C. Hertzog, PI)
- 2004-2007 Consultant  
*Genetic Epidemiology of Alzheimer's Disease in Twins*  
National Institute on Aging (B. Plassman, PI)
- 2000-2008 Co-I, National Steering Committee and BU Site Director  
*Alzheimer's Disease Anti-Inflammatory Prevention Trial*  
\$25,121,319. National Institute on Aging U01-AG15477 (J. Breitner, PI)
- 2003-2008 Consultant  
*Relating Cortical Function to Cerebrovascular and Dementia Risk*  
Veteran's Administration Merit Award (W. Milberg, PI)

Completed Grant Funding (Non-Federal)

- 1985-1986 PI (100% support)  
*Cholinergic Anatomy of Human Epilepsy*  
\$17,000. American Epilepsy Society
- 1986-1988 PI (100% support)  
*Histochemistry of Epilepsy in Human and Animal Brain Tissue*  
\$50,000. Epilepsy Foundation of America
- 1989-1990 PI  
*Analysis of Mossy Fibers in Naturally Occurring Epilepsy*  
\$10,000. Emory University Research Fund
- 1989-1990 Co-I  
*Higher-Level Cognitive Event-Related Potentials*  
\$10,000. Emory University Research Fund (J. Green, PI)
- 1990-1991 Co-I  
*Development of Neuropsychological Methodologies and Techniques for Evaluating Treatment Trials of Dementia*  
\$10,000. Emory University Research Fund (F. Goldstein, PI)
- 1990-1991 PI  
*Plasticity in Mouse Models of Epilepsy*  
\$15,000. Emory University Biomedical Research Support Grant
- 1991 PI  
*The "Eagle Eye" Fund supporting microscope purchase for Alzheimer's Disease research*  
\$72,000. Fraternal Order of Eagles International
- 1992-1993 PI  
*Quality of Life Inventory in Epilepsy Patients*  
\$17,000. Professional Postgraduate Services
- 1993-1994 Co-I  
*Comparison of Fluoxetine/Haloperidol in Agitated Patients with Alzheimer's Disease*  
\$10,000. Emory University Research Fund (A. Auchus, PI)
- 1993-1994 Co-I  
*Cognitive Evoked Potentials*  
\$30,000. Emory/Georgia Tech Biomedical Research Center (J. Green, PI)
- 1997 Co-PI  
*Equipment Grant for Computer Imaging of the Human Brain (PET and fMRI)*  
\$36,000. Georgia State University (John Woodard, PI)

- 1989-1990 PI (10% support)  
*Validation of Computerized Neuropsychological Testing*  
\$124,030. Harvard Risk Management Foundation
- 1999 Co-PI  
*Recovery of Chlamydia Pneumonia from Throat Swabs and Detection of Antibodies in Serum of Alzheimer's Disease Patients*  
\$25,000. Georgia State University, College of Health and Human Sciences (Susan Roman, PI)
- 2000 PI  
*Early Detection of Alzheimer's Disease - Pilot Grant*  
\$50,000. Fraternal Order of Eagles International
- 1992-1993 PI  
*Computer Equipment Grant to Emory University*  
\$415,654. Digital Equipment Corporation
- 1992-1995 PI (Georgia Site)  
*Controlled Study of Ondansetron in the Treatment of Alzheimer's type Dementia*  
\$282,000. Glaxo, Inc.
- 1993-1994 PI (Georgia Site)  
*Efficacy and Safety Study of Besipirdine (HP 749) in Patients with Alzheimer's Disease*  
\$110,000. Hoechst-Roussel
- 1994-1996 PI (Georgia Site)  
*Efficacy and Safety of Sabeluzole in the Treatment of Alzheimer's Disease*  
\$210,000. Janssen Research Foundation
- 1994-1996 PI (Georgia Site)  
*Phase II Study: Safety and Efficacy of CP-118,954 in Subjects with Alzheimer's Disease*  
\$197,000. Pfizer, Inc.
- 1995-1997 PI (Georgia Site)  
*Multicenter Double Blind, Placebo-Controlled Study of Acetyl-L-Carnitine in AD*  
\$128,000 Sigma-Tau Pharmaceuticals
- 1998-1999 PI (Georgia Site)  
*Safety and Efficacy of MK-0966 in Patients at Risk for Alzheimer's Disease*  
Merck Pharmaceuticals and Innovative Medical Research, Inc.  
\$125,000.
- 1995-1997 PI (Georgia Site)  
*A Randomized Double-blind Placebo Controlled Study of SB202026 in Alzheimer's*  
\$139,000. SmithKline Beecham
- 1997-1998 PI (Georgia Site)

- Efficacy and Safety of Galantamine in the Treatment of Alzheimer's Disease*  
\$180,000. Janssen Research Foundation
- 1997-1998 PI (Georgia Site)  
*Safety and Efficacy of Lazabemide in the Treatment of Patients with Alzheimer's Disease*  
\$165,000. Protodyne, Ltd.
- 1998-2000 PI (Georgia Site)  
*A 12-month Treatment Trial of Idebenone (with and without Aricept) in Patients with Alzheimer's Disease*  
\$380,000. Takeda America Research
- 2001-2003 PI (Boston University Site)  
*Clinical Assessment of the Performance of the Alkon Calcium Response Ratio (CAVEAT))*  
\$120,000. NeuroLogic, Inc.
- 1998-2003 PI  
*Memory Assessment Screening and Therapeutics in Elderly Residents (MASTERS)*  
\$90,000. Pfizer Inc.
- 2001-2004 Co-I  
*Pharmacologic vs Pharmacologic-Behavioral Interventions for Apathy in Alzheimer's Disease*  
\$100,000. Alzheimer's Association (P. Boyle, PI)
- 2002-2004 Co-I  
*Illness Perceptions Among Caregivers and Relatives of People with Alzheimer's Disease*  
\$100,000. Alzheimer's Association (S. Roberts, PI)
- 2002-2004 Co-I  
*REVEAL: Development of an Empirically Based Decision-Making Model*  
\$120,000. Alzheimer's Association (A. Hurley, PI)
- 2003-2005 Co-I  
*Genetics of Vascular Neuropathology and Alzheimer's Disease*  
\$100,000. Alzheimer's Association (A. Yip, PI)
- 2005-2008 National Co-PI and Site PI (Boston University Site)  
*Phase III Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer's Type*  
\$450,000. Myriad Pharmaceuticals, Inc.

## Publications

### *Peer-Reviewed Articles (\* indicates member of Group Authorship)*

1. Trojanowski JQ, **Green RC**, Levine DM: Crossed aphasia in a dextral: A clinicopathological study. Neurology, 30: 709-713, 1980.
2. Mesulam M-M, Volicer L, Marquis JK, Mufson EJ, **Green RC**: Systemic regional differences in the cholinergic innervation of the primate cerebral cortex: Distribution of enzyme activities and some behavioral implications. Annals of Neurology, 19:144-151, 1986.
3. Pitman RK, **Green RC**, Jenike M, Mesulam M-M: Clinical Comparison of Obsessive Compulsive Disorder and Tourette Syndrome. American Journal of Psychiatry, 144: 1166-1171, 1987.
4. **Green RC**, Mesulam M-M: Acetylcholinesterase fiber staining in the human hippocampus and parahippocampal gyrus. Journal of Comparative Neurology, 273: 488-499, 1988.
5. **Green RC**, Adler JR, Erba GA: Epilepsy surgery in children. Journal of Child Neurology, 3:155-160, 1988.
6. **Green RC**, Elizondo BJ: A non-stereotaxic method for olfactory bulb kindling reveals distinct kindling rates among inbred mouse strains. Journal of Neuroscience Methods, 27:109-113, 1989.
7. **Green RC**, Blume HW, Kupferschmid SB, Mesulam M-M: Alterations of hippocampal acetylcholinesterase in human temporal lobe epilepsy. Annals of Neurology, 26:347-351, 1989.
8. **Green RC**, Seyfried TN: Kindling susceptibility and genetic seizure predisposition in inbred mice. Epilepsia, 32:22-26, 1991.
9. Malko JA, Hoffman JC, **Green RC**: MR measurement of intracranial CSF volume in 41 elderly normal volunteers. American Journal of Neuroradiology, 12:371-374, 1991.
10. Goldstein FC, Green J, Presley R, **Green RC**: Dysnomia in Alzheimer's disease: An evaluation of neurobehavioral subtypes. Brain and Language, 43:308-322, 1992.
11. **Green RC**, Goldstein FC, Auchus AP, Presley R, Van Tuyl L, Green J, Hersch SM, Karp HR: Treatment trial of oxiracetam in Alzheimer's disease. Archives of Neurology, 49:1135-1136, 1992.
12. Wolf SL, Kutner NG, **Green RC**, McNeely E: The Atlanta FICSIT study: Two exercise interventions to reduce frailty in elders. Journal of the American Geriatrics Society, 41:329-332, 1993.
13. Gutekunst C-A, Hartney A, Rees HD, **Green RC**: Lack of strain differences in spatial learning among seizure prone and seizure-resistant mice. Behavior Genetics, 23:385-389, 1993.

14. **Green RC**, Rees HD, Feller DJ: Olfactory bulb kindling in mice susceptible and resistant to ethanol withdrawal. Epilepsia, 34:416-419, 1993.
15. Green J, Goldstein FC, Sirokman B, **Green RC**: Variable awareness of deficits in Alzheimer's disease. Neuropsychiatry, Neuropsychology, and Behavioral Neurology, 6:159-165, 1993.
16. **Green RC**, Green J, Harrison J, Kutner M: Screening for cognitive impairment in older individuals: Validation study of a computer-based test. Archives of Neurology, 51:779-786, 1994.
17. Auchus AP, Goldstein FC, Green J, **Green RC**: Unawareness of cognitive impairments in Alzheimer's disease. Neuropsychiatry, Neuropsychology, and Behavioral Neurology, 7:25-29, 1994.
18. Goldman WP, Winograd E, Goldstein FC, O'Jile J, **Green RC**: Source memory in Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 16:105-116, 1994.
19. White R, Cohen R, Gerr F, **Green RC**, Lezak M, Lybarger J, Mack J, Silbergeld E, Valciukas J: Criteria for progressive modification of neurobehavioral batteries. Neurotoxicol Teratol, 16:511-524, 1994.
20. Auchus AP, Freeman A, **Green RC**: Agitated behavior relieved following botulinum toxin treatment of cervical dystonia in dementia. Neurology 45:393, 1995.
21. **Green RC**, Benjamin S, Cummings JL: Fellowship programs in behavioral neurology. Neurology, 45:412-415, 1995.
22. Province MA et al. (for the FICSIT Group): The effects of exercise on falls in elderly patients: A preplanned meta-analysis of the FICSIT trials. Journal of the American Medical Association, 273:13-17-1396, 1995.\*
23. **Green RC**, Woodard JL, Green J: Validity of the Mattis Dementia Rating Scale for detection of cognitive impairment in the elderly. Journal of Neuropsychiatry and Clinical Neurosciences, 7:357-360, 1995.
24. **Green RC**, Goldstein FC, Mirra SS, Alazraki N, Baxt J, Bakay RAE: Slowly progressive apraxia in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 59:312-315, 1995.
25. Farrer LA, Cupples LA, van Duijn CM, Kurz A, Zimmer R, Müller U, **Green RC**, Clarke V, Shoffner J, Wallace DC: Apolipoprotein E genotype in patients with Alzheimer's disease: Implications for the risk of dementia among relatives. Annals of Neurology, 38:797-808, 1995.
26. Rao VS, Cupples LA, Auerbach SA, Becker R, Burke J, Chui H, Duara R, Foley EJ, Glatt SL, **Green RC**, et al: Age at onset of Alzheimer disease is influenced by multiple genetic and non-genetic factors. Alzheimer's Research 1:159-168, 1995.

27. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, **Green RC**, et al: Reduction of amyloid beta peptide<sub>42</sub> in the CSF of Alzheimer's disease patients. Annals of Neurology, 38:643-648, 1995.
28. Woodard JL, Salthouse T, **Green RC**: Confirmatory factor analysis of the Mattis Dementia Rating Scale in patients with Alzheimer's disease. Psychological Assessment, 8:85-91, 1996.
29. Goldstein FC, Green J, Presley R, O'Jile J, Freeman A, Watts R, **Green RC**: Cognitive estimation in Alzheimer's disease. Neuropsychiatry, Neuropsychology and Behavioral Neurology, 9:35-42, 1996.
30. Green J, Woodard JL, Sirokman BE, Zakers GO, Maier CL, **Green RC**, Watts RL: Event-related potential P3 amplitude increase as a measure of brain dysfunction in mild Parkinson's disease. Movement Disorders, 11:32-42, 1996.
31. **Green RC**, Kellerman AL: Grandfather's guns: When should we intervene? (editorial) Journal of the American Geriatrics Society, 44:467-469, 1996.
32. Loupe DN, Newman JN, **Green RC**, et al: Pupillary response to tropicamide in patients with Alzheimer's disease. Ophthalmology, 103:495-503, 1996.
33. Huff FJ, Antuono P, Delagandara J, McDonald M, Cutler N, Holub R, Cohen S, **Green RC**, et al: A treatment and withdrawal trial of Besipirdine in Alzheimer's disease. Alzheimer's Disease and Associated Disorders, 10:93-102, 1996.
34. Lautenschlager NT, Cupples LA, Rao VS, Auerbach SA, Burke J, Chui H, Duara R, Foley EJ, Glatt S, **Green RC**, et al: Risk of dementia among relatives of Alzheimer disease patients in the MIRAGE study: What is in store for the "oldest old"? Neurology, 46:641-650, 1996.
35. **Green RC**, Benjamin S, Cummings JL: Survey instrument for assessment of Behavioral Neurology training programs. [On-line], [CD-ROM]. Abstract from: CDP File: HaPI-CD, 1996.
36. Roberts VJ, Ingram SM, Lamar M, **Green RC**: Prosody impairment and associated affective and behavioral disturbances in Alzheimer's disease. Neurology, 47:1482-1488, 1996.
37. Letz R, **Green RC**, Woodard JL: Development of a computer-based battery designed to screen adults for neuropsychological impairment. Neurotoxicol Teratol, 18:365-370, 1996.
38. Wolf SL, Barnhart HX, Kutner NG, McNeely E, Coogler C, Tingsen X, et al: Reducing frailty and falls in older persons: An investigation of Tai Chi and computerized balance training. Journal of the American Geriatrics Society, 44:489-497, 1996.\*
39. Rao VS, Cupples LA, van Duijn CM, Kurz A, **Green RC**, et al: Evidence for major gene inheritance of Alzheimer disease in families of patients with and without ApoE e4. American Journal of Human Genetics, 59:664-675, 1996.

40. Galasko D, Brown J, Clark C, Chang L, Miller B, **Green RC**, Motter R, Seubert P: Assessment of cerebrospinal fluid levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology, 48:632-635, 1997.
41. **Green RC**, Clarke VC, Thompson NJ, Woodard JL, Letz R: Early detection of Alzheimer's disease: Methods, markers and misgivings. Alzheimer Disease and Associated Disorders, 11:S1-5, 1997.
42. Farrer LA, Cupples LA, Kukull WA, Volicer L, Wells JM, Kurz A, **Green RC**, Chui H, et al: Risk of Alzheimer disease is associated with parental age among apolipoprotein E e4 heterozygotes. Alzheimer's Research, 3:83-91, 1997.
43. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al: Effects of age, gender and ethnicity on the association between Apolipoprotein E genotype and Alzheimer disease. Journal of the American Medical Association, 278:1349-1356, 1997.
44. Woodard JL, Auchus AP, Godsall RE, **Green RC**: An analysis of test bias due to race on the Mattis Dementia Rating Scale. Journal of Gerontology: Psychological Sciences, 53B:P370-P374, 1998.
45. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, **Green RC**, et al: High cerebrospinal fluid tau and low amyloid  $\beta_{42}$  levels in the clinical diagnosis of Alzheimer's disease and relation to Apolipoprotein E genotype. Archives of Neurology, 55:937-945, 1998.
46. Woodard JL, Grafton ST, Votaw JR, **Green RC**, Dobraski ME, Hoffman JM: Compensatory recruitment of neural resources during overt rehearsal in Alzheimer's disease. Neuropsychology, 2:491-504, 1998.
47. Kutner NG, Brown PJ, Stavisky RC, Clark WS, **Green RC**: "Friendship" interactions and expression of agitation among residents of a dementia care unit: Six-month observational data. Research on Aging 22:188-205, 2000.
48. Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H, **Green RC**, et al: Head injury and the risk of Alzheimer disease in the MIRAGE study. Neurology, 54:1316-1323, 2000.
49. Letz R, Gerr F, Cragle D, **Green RC**, Watkins J, Fidler AT: Residual neurologic deficits 30 years after occupational exposure to elemental mercury. Neurotoxicology, 21:459-474, 2000.
50. Gerr F, Letz R, Ryan PB, **Green RC**: Neurological effects of environmental exposure to arsenic in dust and soil among humans. Neurotoxicology, 21:475-488, 2000.
51. Gerr F, Letz R, **Green RC**: Relationships between quantitative measures and neurologist's clinical rating of tremor and standing steadiness in two epidemiological studies. Neurotoxicology, 21:730-760, 2000.

52. Demissie S, **Green RC**, et al.: Reliability of information collected by proxy in family studies of Alzheimer's disease. Neuroepidemiology, 20:105-111, 2001.
53. Carlson MC, Zandi PP, Plassman BL, Tschanz JT, Welsh-Bohmer KA, Steffens DC, Bastian LA, Mehta KM, Breitner JC; Cache County Study Group: Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study. Neurology 57(12): 2210-2216, 2001.\*
54. **Green RC**, Cupples LA, Go R, Edeki T, Griffith P, Williams MP, Hipps Y, Graff-Radford N, Bachman D, Farrer LA. Risk of dementia among white and African American relatives of Alzheimer's disease patients. Journal of the American Medical Association, 287:329-336, 2002.
55. Graff-Radford N, **Green RC**, Go R, Edeki T, Bachman D, Griffith P, Williams M, Hipps Y, Haines JL, Cupples LA, Farrer LA: Association between APOE genotype and Alzheimer disease in African Americans. Archives of Neurology, 59:594-600, 2002.
56. **Green RC**: Genetic susceptibility testing for Alzheimer's disease: Has the moment arrived? Alzheimer's Care Quarterly, 3:208-214, 2002.
57. Tschanz JT, Welsh-Bohmer KA, Plassman BL, Norton MC, Wyse BW, Breitner JC; Cache County Study Group: An adaptation of the modified mini-mental state examination: analysis of demographic influences and normative data: the cache county study. Neuropsychiatry Neuropsychology and Behavioral Neurology, 15(1): 28-38, 2002.\*
58. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC; Cache County Study Investigators: Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology, 59(6):880-886, 2002.\*
59. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JC; Cache County Memory Study Investigators: Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. Journal of the American Medical Association, 288(17): 2123-2129, 2002.\*
60. Hipps YG, Roberts JS, **Green RC**: Differences between African Americans and whites in their attitudes toward genetic testing for Alzheimer's disease. Genetic Testing, 7:39-44, 2003.
61. Roberts JS, Connell CM, Cisewski D, Hipps YG, Demissie S, **Green RC**: Differences in perceptions of Alzheimer's disease between African Americans and White Americans. Alzheimer's Disease and Associated Disorders, 17:19-26, 2003.
62. **Green RC**, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, DeCarli C, Kukull W, Chui H, Edeki T, Griffith P, Friedland RP, Bachman D, Farrer LA: Depression as a risk factor for Alzheimer disease: The MIRAGE Study. Archives of Neurology, 60:753-759, 2003.
63. Bachman DL, **Green RC**, Benke K, Cupples LA, Farrer LA: Comparison of Alzheimer's Disease Risk Factors in White and African American families: The MIRAGE Study. Neurology, 60:3072-1374, 2003.

64. Hayden KM, Khachaturian AS, Tschanz JT, Corcoran C, Nortond M, Breitner JC; Cache County Study Group: Characteristics of a two-stage screen for incident dementia. Journal of Clinical Epidemiology, 56(11): 1038-45, 2003.\*
65. Steffens DC, Norton MC, Hart AD, Skoog I, Corcoran C, Breitner JC; Cache County Study Group: Apolipoprotein E genotype and major depression in a community of older adults. The Cache County Study. Psychological Medicine, 33(3): 541-7, 2003.\*
66. Roberts JS, LaRusse SA, Katzen H, Whitehouse PJ, Barber M, Post SG, Relkin N, Quaid K, Pietrzak RH, Cupples LA, Farrer LA, Brown T, **Green RC**: Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer's disease. Alzheimer's Disease and Associated Disorders, 17:86-93, 2003.
67. Cupples LA, Farrer LA, Sadovnick D, Relkin N, Whitehouse P, **Green RC**: Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: The REVEAL Study. Genetics in Medicine, 6:192-196, 2004.
68. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC; Cache County Study Group: Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Archives of Neurology, 61(1): 82-8, 2004.\*
69. Roberts JS, Barber M, Brown T, Cupples LA, Farrer L, LaRusse SA, Post S, Quaid K, Ravdin L, Relkin N, Sadovnick D, Whitehouse P, Woodard J, **Green RC**: Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multi-site, randomized clinical trial. Genetics in Medicine, 6:197-203, 2004.
70. Tschanz, J.T., Corcoran, C., Skoog, I., Khachaturian, A.S., Heath, J., Hayden, K.M., Welsh-Bohmer, K.A., Calvert, T., Breitner, J.C.S., on behalf of the Cache County Study Group: Dementia: A leading predictor of death after age 85 in a defined elderly population. The Cache County Study. Neurology, 62:1156-62, 2004.\*
71. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC; Cache County Study Investigators: Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Archives of General Psychiatry, 61(5): 518-24, 2004.\*
72. Henderson VW, Benke KS, **Green RC**, Cupples LA, Farrer LA: Postmenopausal hormone therapy and Alzheimer's disease risk: Interaction with age. Journal of Neurology, Neurosurgery and Psychiatry, 76:103-105, 2005.
73. LaRusse SA, Roberts JS, Marteau T, Katzen H, Linnenbringer E, Barber M, Whitehouse P, Quaid K, Brown T, **Green RC**, Relkin N: Predictive genetic testing for Alzheimer's disease: Impact on perceived risk of Alzheimer's disease. Genetics in Medicine, 7:48-53, 2005.
74. Yip AG, **Green RC**, Huyck M, Cupples LA, Farrer LA. Nonsteroidal anti-inflammatory drug use and Alzheimer disease risk: The MIRAGE Study. Biomed Central Geriatrics, 5:2, 2005

75. Marteau T, Roberts JS, LaRusse SA, **Green RC**: Predictive genetic testing for Alzheimer's disease: Impact upon perceived risk of Alzheimer's disease. Risk Analysis, 25:397-404, 2005.
76. Zick CD, Matthews C, Roberts JS, Cook-Deegan, R, Pokorski RJ, **Green RC**: Genetic susceptibility testing for Alzheimer's disease and its impact on health insurance behavior. Health Affairs, 24:483-490, 2005.
77. Yip G, McKee A, **Green RC**, Wells J, Young H, Cupples LA, Farrer LA: APOE, vascular pathology and the AD brain. Neurology, 65:259-265, 2005.
78. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC; Cache County Study Investigators: Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Archives of General Psychiatry, 62(2): 217-24, 2005.\*
79. Lyketsos CG, Toone L, Tschanz J, Rabins PV, Steinberg M, Onyike CU, Corcoran C, Norton M, Zandi P, Breitner JC, Welsh-Bohmer K, Anthony J, Ostbye T, Bigler E, Pieper C, Burke J, Plassman B, **Green RC**, Steffens DC, Klein L, Leslie C, Townsend JJ, Wyse BW, Munger R, Williams M. Population-based study of medical comorbidity in early dementia and "cognitive impairment, no dementia (CIND)": association with functional and cognitive impairment: The Cache County Study. American Journal of Geriatric Psychiatry, 13:656-654, 2005.
80. Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, **Green RC**: Genetic risk assessment for adult children of people with Alzheimer's disease. Journal of Geriatric Psychiatric Neurology, 18:250-255, 2005.
81. Bastian LA, West NA, Corcoran C, Munger RG; Cache County Study on Memory, Health, and Aging: Number of children and the risk of obesity in older women. Preventive Medicine, 40(1): 99-104, 2005.\*
82. Hurley AC, Harvey R, Roberts JS, Wilson-Chase C, Lloyd S, Prest J, Lock M, Horvath KJ, **Green RC**: Genetic susceptibility for Alzheimer's disease: Why did adult offspring seek testing? American Journal of Alzheimer's Disease and Other Dementias, 20:374-381, 2005.
83. Tschanz JT, Treiber K, Norton MC, Welsh-Bohmer KA, Zandi PP, Szekely CA, Toone L, Munger RG, Lyketsos C, Breitner JCS, and the Cache County Study Group: A population study of Alzheimer's disease: findings from The Cache County Study on Memory, Health and Aging. Care Management Journal, 6:107-14, 2005.\*
84. Hayden KM, Zandi PP, Lyketsos CG, Tschanz JT, Norton MC, Khachaturian AS, Pieper CF, Welsh-Bohmer KA, Breitner JC; Cache County Investigators: Apolipoprotein E genotype and mortality: findings from the Cache County Study. Journal of the American Geriatric Society, 53(6):935-42, 2005.\*

85. Erlich PM, Lunetta KL, Cupples LA, Huyck M, **Green RC**, Baldwin CT, Farrer LA: Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Human Molecular Genetics, 15:77-85, 2006.
86. **Green RC**, McNagny SE, Jayakumar P, Cupples LA, Benke K, Farrer LA: Statin use and the risk of Alzheimer's disease. Alzheimer's and Dementia, 2:96-103, 2006.
87. Tsai DH, **Green RC**, Benke KS, Silliman RA, Farrer LA: Predictors of subjective memory complaint in cognitively normal relatives of patients with Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neuroscience, 18:384-388, 2006.
88. Wolozin B, Manger J, Bryant R, Cordy J, **Green RC**, McKee A. Cholesterol, Alzheimer's disease and statins: Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neuropathologica 114:63-70, 2006.
89. Tschanz JT, Welsh-Bohmer KA, Lyketsos CG, Corcoran C, **Green RC**.... Breitner JCS: Conversion to dementia from mild cognitive disorder: the Cache County Study. Neurology, 67:229-234, 2006.
90. Østbye T, Krause KM, Norton MC, Tschanz J, Sanders L, Hayden K, Pieper C, Welsh-Bohmer KA; Cache County Investigators: Ten dimensions of health and their relationships with overall self-reported health and survival in a predominately religiously active elderly population: the cache county memory study. Journal of the American Geriatric Society, 54(2):199-209, 2006.\*
91. Norton MC, Skoog I, Toone L, Corcoran C, Tschanz JT, Lisota RD, Hart AD, Zandi PP, Breitner JC, Welsh-Bohmer KA, Steffens DC; Cache County Investigators: Three-year incidence of first-onset depressive syndrome in a population sample of older adults: the Cache County study. American Journal of Geriatric Psychiatry, 14(3):237-245, 2006.\*
92. Norton MC, Skoog I, Franklin LM, Corcoran C, Tschanz JT, Zandi PP, Breitner JC, Welsh-Bohmer KA, Steffens DC; Cache County Investigators: Gender differences in the association between religious involvement and depression: the Cache County (Utah) study. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 61(3):P129-136, 2006.\*
93. Hayden KM, Zandi PP, Lyketsos CG, Khachaturian AS, Bastian LA, Charoonruk G, Tschanz JT, Norton MC, Pieper CF, Munger RG, Breitner JC, Welsh-Bohmer KA; Cache County Investigators: Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Disease and Associated Disorders, 20(2):93-100, 2006.\*
94. Akomolafe A, Lunetta KL, Erlich PM, Cupples LA, Baldwin CT, Huyck M, **Green RC**, Farrer LA: Genetic association between endothelial Nitric Oxide Synthase (NOS3) and Alzheimer disease. Clinical Genetics, 70:49-56, 2006.
95. Jefferson AL, Wong S, Bolen E, Ozonoff A, **Green RC**, Stern RA: Cognitive correlates of HVOT performance differ between individuals with mild cognitive impairment and normal controls. Archives of Clinical Neuropsychology, 21:405-412, 2006.

96. Binetti G, Benussi L, Roberts S, Villa A, Pasqualetti P, Sheu C-F, Gigola L, Lussignoli G, Dal Forno G, Barbiero L, Corbellini, **Green RC**, Rossini PM, Ghidoni R: Areas of intervention for genetic counselling of dementia: Cross-cultural comparison between Italians and Americans. Patient Education and Counseling, 64:285-293, 2006.
97. Lyketsos CG, Toone L, Tschanz J, Corcoran C, Norton M, Zandi P, Munger R, Breitner JC, Welsh-Bohmer K; Cache County Study Group: A population-based study of the association between coronary artery bypass graft surgery (CABG) and cognitive decline: the Cache County study. International Journal of Geriatric Psychiatry, 21(6): 509-18, 2006.
98. **Green RC**, Dekosky ST: Primary prevention trials in Alzheimer's disease. Neurology, 67:S2-5, 2006.
99. Gooding HC, Linnebringer EL, Burack J, Roberts JS, **Green RC**, Biesecker BB: Genetic susceptibility testing for Alzheimer disease: Motivation to obtain information and control as precursors to coping with increased risk. Patient Education and Counseling, 64:259-267, 2006.
100. Eckert SL, Katzen H, Roberts JS, Barber M, Ravdin LD, Relkin NR, Whitehouse PJ, **Green RC**: Recall of disclosed Apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: The REVEAL Study. Genetics in Medicine, 8:746-751, 2006.
101. Akomolafe A, Beiser A, Meigs JB, Au R, Green RC, Farrer LA, Wolf PA, Seshadri S: Diabetes mellitus and risk of developing Alzheimer disease. Archives of Neurology 63:1551-1555, 2006.
102. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PloS Clinical Trials, 1(7):e33, 2006.\*
103. Rogaeva E, Meng Y, Lee JH, Gu Y-J, Kawarai T, Katayama T, Erlich PM, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Cupples LA, **Green RC**....St. George-Hyslop, P: The sortilin-related receptor SorLA is associated with Alzheimer's disease. Nature Genetics, 39:168-77, 2007.
104. Onyike CU, Sheppard JME, Tschanz JT, Mayer LS, **Green RC**... Lyketsos CG: Epidemiology of apathy in older adults: The Cache County Study. Journal of Geriatric Psychiatry, 15(5):365-75, 2007.
105. Jefferson AL, Wong S, Gracer TS, Ozonoff A, **Green RC**, Stern RA. Geriatric performance on an abbreviated version of the Boston Naming Test. Applied Neuropsychology, 14:1-9, 2007.
106. Lyketsos CG, Breitner JCS, **Green RC**, Martin BK, Piantadosi S, Sabbagh M: Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial (ADAPT). Neurology, 68(21):1800-1808, 2007.
107. Lunetta KL, Erlich PM, Cuenco KT, Cupples LA, **Green RC**, Farrer LA, DeCarli C: Heritability of Magnetic Resonance Imaging (MRI) traits in Alzheimer disease cases and their siblings in the MIRAGE Study. Alzheimer's Disease and Associated Disorders, 21(2):85-91, 2007.

108. Cuenco KR, **Green RC**, Zhang J, Lunetta K, Erlich PM, Cupples LA, Farrer LA, DeCarli C: Magnetic resonance imaging traits in siblings discordant for Alzheimer disease. Journal of Neuroimaging, in press.
109. Mielke MM, Rosenberg PB, Tschanz J, Cook L, Corcoran C, Hayden KM, Norton M, Rabins PV, **Green RC**, Welsh-Bohmer KA, Breitner JCS, Munger R, Lyketsos CG: Vascular factors predict rate of functional decline in Alzheimer's disease. Neurology, 69(19):1850-8, 2007.
110. Hayden KM, Zandi PP, Khachaturian AS, Szekely CA, Fotuhi M, Norton MC, Tschanz JT, Pieper CF, Corcoran C, Lyketsos CG, Breitner JC, Welsh-Bohmer KA; Cache County Investigators: Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology, 69(3):275-282, 2007.\*
111. Hayden KM, Welsh-Bohmer KA, Wengreen HJ, Zandi PP, Lyketsos CG, Breitner JC and Cache County Investigators: Risk of mortality with vitamin E supplements: the Cache County study. American Journal of Medicine, 120(2):180-184, 2007.\*
112. Fearing MA, Bigler ED, Norton M, Tschanz JA, Hulette C, Leslie C, Welsh-Bohmer K; Cache County Investigators: Autopsy-confirmed Alzheimer's disease versus clinically diagnosed Alzheimer's disease in the Cache County Study on Memory and Aging: A comparison of quantitative MRI and neuropsychological findings. Journal of Clinical and Experimental Neuropsychology, 29(5):553-560, 2007.\*
113. Boyes RG, Gunter JL, Frost C, Janke AL, Yeatman T, Hill DL, Bernstein MA, Thompson PM, Weiner MW, Schuff N, Alexander GE, Killiany RJ, DeCarli C, Jack CR, Fox NC; ADNI Study: Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. Neuroimage, 39(4):1752-62, 2008.\*
114. Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, **Green RC**: Health behavior changes after genetic risk assessment for Alzheimer's disease: The REVEAL Study. Alzheimer's Disease and Associated Disorders, 22:94-97, 2008.
115. Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, Breitner JC, Steffens DC, Tschanz JT; Cache County Investigators: Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. International Journal of Geriatric Psychiatry, 23(2):170-177, 2008.\*
116. Treiber KA, Lyketsos CG, Corcoran C, Steinberg MD, Norton M, **Green RC**, Rabins P, Stein DM, Welsh-Bohmer KA, Breitner JCS, Tschanz JT: Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: The Cache County Study. International Psychogeriatrics, 20(3):538-53, 2008.
117. Rosenberg PB, Mielke MM, Tschanz J, Rabins P, **Green RC**, Norton M, Corcoran C, Welsh-Bohmer KA, Breitner JCS, Munger R, Lyketsos CG: Effects of beta-blockers and lipid-lowering agents on rate of functional decline in Alzheimer's disease. American Journal Geriatric Psychiatry, in press.

118. Ashendorf L, Jefferson AL, O'Connor MK, Chaisson C, **Green RC**, Stern RA: Trail Making Test errors in normal aging, mild cognitive impairment, and dementia. Archives of Clinical Neuropsychology, 23:129-137, 2008.
119. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E; Cross Trial Safety Assessment Group: Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation, 117(16):2104-13, 2008.\*
120. Norton MC, Singh A, Skoog I, Corcoran C, Tschanz JT, Zandi PP, Breitner JC, Welsh-Bohmer KA, Steffens DC; Cache County Investigators: Church attendance and new episodes of major depression in a community study of older adults: the Cache County Study. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 63(3):P129-37, 2008.\*
121. Horsdal HT, Olesen AV, Gasse C, Sorensen HT, **Green RC**, Johnsen SP: Use of statins and risk of hospitalization with dementia: A Danish population-based case-control study. Alzheimer's Disease and Associated Disorders, in press.
122. Christenson KD, Roberts JS, Royal CDM, Fasaye G, Obisesan T, Cupples LA, Whitehouse PJ, Butson MB, Linnenbringer E, Relkin NR, Farrer L, Cook-Deegan R, **Green RC**: Incorporating ethnicity into genetic risk assessment for Alzheimer's disease: The REVEAL Study experience. Genetics in Medicine, 10: 207-214, 2008.
123. Fanshawe TR, Prevost AT, Roberts JS, **Green RC**, Armstrong D, Marteau TM: Explaining behaviour change after genetic testing: The problem of collinearity between test results and risk estimations. Genetic Testing, in press.
124. Chung WW, Chen CA, Cupples LA, Roberts JS, Hiraki SC, Nair AK, **Green RC**, Stern RA: A new scale measuring psychological impact of genetic susceptibility testing for Alzheimer's disease. Alzheimer's Disease and Associated Disorders, in press.
125. Szekely CA, **Green RC**, Breitner JCS, Ostbye T, Beiser AS, Corrada MM, Dodge HH, Ganguli M, Kawas CH, Kuller LH, Psaty BM, Resnick SM, Wolf PA, Zonerman AB, Welsh-Bohmer KA, Zandi PP: No advantage of "AB42-lowering" NSAIDs for prevention of AD in six pooled cohort studies. Neurology, in press.
126. Martin BK, Brandt J, Breitner JCS, Craft S, Evans D, **Green RC**, Mullen M, Piantadosi S, Szekely C: Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib. Archives of Neurology, 2008.
127. ADAPT Research Group: Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib. Archives of Neurology, in press.\*

128. Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, L Whitwell J, Ward C, Dale AM, Felmlee JP, Gunter JL, Hill DL, Killiany R, Schuff N, Fox-Bosetti S, Lin C, Studholme C, DeCarli CS, Krueger G, Ward HA, Metzger GJ, Scott KT, Mallozzi R, Blezek D, Levy J, Debbins JP, Fleisher AS, Albert M, **Green RC**, Bartzokis G, Glover G, Mugler J, Weiner MW, ADNI Study: The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. Journal of Magnetic Resonance Imaging, 27(4):685-91, 2008.
129. Cassidy MR, Roberts JS, Bird TD, Steinbart EJ, Cupples LA, Chen CA, Linnenbringer E, **Green RC**: Comparing test-specific distress for susceptibility vs. deterministic genetic testing for Alzheimer's disease. Alzheimer's and Dementia, in press.
130. Cuenco KT, Lunetta K, Baldwin CT, McKee AC, Guo J, Cupples LA, **Green RC**, St. George-Hyslop, PH, Chui H, DeCarli C, Farrer LA for the MIRAGE Study Group: Distinct variants in SORL1 are associated with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Archives of Neurology, in press.
131. Ashendorf L, Jefferson AL, **Green RC**, Stern RA: Test-retest stability on the WRAT-3 reading subtest in geriatric cognitive evaluations. Journal of Clinical and Experimental Neuropsychology, in press.
132. Hiraki S, Chen CA, Roberts JS, Cupples LA, **Green RC**: Perceptions of familial risk in those seeking genetic risk assessment for Alzheimer's disease. Journal of Genetic Counseling, in press.

*Publications in Submission or Preparation*

Green RC, et al: A randomized, controlled trial to evaluate the impact of APOE disclosure in relatives of patients with Alzheimer's disease: The REVEAL Study. in submission.

Ashida S, et al: Disclosing the disclosure: Factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. in submission.

Gramling B, et al: Genetic testing in utero for susceptibility to adult onset disorders: Survey results from the REVEAL Study. in submission.

Nair A, et al: Race and low self-perceived risk are associated with dropout in a study disclosing genetic susceptibility for Alzheimer's disease. in submission.

Roberts S, et al: Age-group differences in the impact of genetic susceptibility testing with APOE disclosure. in preparation.

Linnenbringer E, et al: "I know what you told me, but here is what I think": Self-perceived risk after genetic disclosure in the REVEAL Study. in preparation.

Akinleye D et al: Differences between African American and White research volunteers in their attitudes, beliefs and knowledge toward genetic testing for Alzheimer's disease. in preparation.

Kopits I, et al: How much will individuals pay for genetic risk information: The REVEAL Study. in preparation.

*Chapters and Review Articles*

1. **Green RC**, Pitman RK: Tourette Syndrome and Obsessive Compulsive Disorder. in Jenike M (ed). Obsessive Compulsive Disorders: Theory and Management. PSG Publishing, Littleton, MA, 1986, Revised 2nd edition, 1990.
2. **Green RC**: Neuropathology and behavior in epilepsy. in Devinsky O, Theodore WH (eds) Epilepsy and Behavior. Wiley-Liss, New York, 1991, 345-359.
3. Hersch SM, Goldstein FC, **Green RC**: The mental status examination in neurology. in Hurst JW et al. (eds) Medicine for the Practicing Physician, Fourth Edition. Butterworth-Heinemann, Boston, pp 1673-1677, 1992.
4. Mackay BC, **Green RC**: Confusional states and disorders of attention. in Hurst JW et al. (eds) Medicine for the Practicing Physician, Fourth Edition. Butterworth-Heinemann, Boston, pp 1677-1679, 1992.
5. Bachman DL, **Green RC**: Speech and language disorders. in Hurst JW et al. (eds) Medicine for the Practicing Physician, Fourth Edition. Butterworth-Heinemann, Boston, pp 1684-1687, 1992.
6. **Green RC**, Devinsky O: Complex motor manifestations and directed aggression in epilepsy. in Joseph AB, Young RR (eds.) Disorders of Movement in Psychiatry and Neurology. Blackwell Scientific, pp 738-748, 1992.
7. **Green RC**, Walker HK, Morris R: Disorders of memory. in Hurst JW et al. (eds) Medicine for the Practicing Physician, Fourth Edition. Butterworth-Heinemann, Boston, pp 1679-1684, 1992.
8. Wolf SL, Coogler C, **Green RC**, Xu T: Novel interventions to prevent falls in the elderly. in Perry HM, Morely JE, Coe RM (eds) Aging and Musculoskeletal Disorders: Concepts, Diagnosis and Treatment. Springer, pp 178-195, 1993.
9. Auchus AP, **Green RC**, Nemeroff CB. Cortical and subcortical neuropeptides in Alzheimer's disease. Neurobiology of Aging.15:589-595, 1994
10. Goldstein FC, **Green RC**: Assessment of reasoning, problem-solving and executive functions. in Mapou RL, Spector J (eds) Clinical Neuropsychological Assessment: A Cognitive Approach. Plenum Press, New York, pp 49-81, 1995.
11. Olson D, Auchus AP, **Green RC**: Dementia. in: Lubin MF, Walker HK, Smith RB (eds) Medical Management of the Surgical Patient, Third Edition. JB Lippincott Company, Philadelphia, pp 361-367, 1995.

12. Dihenia B, **Green RC**: Non-Alzheimer's degenerative dementias. Current Opinions in Psychiatry. 8:51-56, 1995.
13. **Green RC**: Alzheimer's Disease and Other Dementing Disorders in Adults. in Joynt RJ (ed.) Clinical Neurology. Harper and Row, Philadelphia, pp 1-84, 1995.
14. **Green RC**: Norman Geschwind's Contributions to Dementia. in Schacter SC, Devinsky O (eds.) Behavioral Neurology and the Legacy of Norman Geschwind. Lippincott-Raven, pp 163-169, 1997.
15. Cisewski D, **Green RC**, Welsh-Bohmer K: Mental status screening in evaluation of dementia. in Rizzo M, Eslinger PJ (eds) Neuropsychology and Neurobehavioral Disorders. pp 25-46, 2004.
16. Christensen DD, **Green RC**: Disease modifying therapies for Alzheimer's disease: Update on emerging treatments. CNS News, November, 2005, pp 21-26.
17. Nair A, **Green RC**: Alzheimer's disease at 100 years. Practical Neurology. 5:22-29, 2006.
18. Mandell A, **Green RC**: Diagnosis and treatment of Alzheimer's disease. In Kowell N, Budson A (eds) Alzheimer's Disease and Other Dementia. Blackwell Publishing, in press.

*Commentary, Letters and Brief Reviews*

1. **Green RC**: Book Review of Bigler, Yeo and Turkheimer (eds.) *Neuropsychological Function and Brain Imaging*. Neurosurgery, 26:715, 1990.
2. **Green RC**: Book Review of Duvernoy HM: *The Human Hippocampus*. Journal of Epilepsy, 4:57-58, 1991.
3. Goldstein FC, **Green RC**: Book Review of Rose FD and Johnson DA (eds.) *Recovery from Brain Damage: Reflections and Directions*. Neurosurgery, 80:347-348, 1994.
4. Contributor to Sections on Dementia and Delirium: Diagnosics and Statistical Manual of Mental Disorders – IV, American Psychiatric Association, 1995.
5. Auchus AP, Woodard JL, Goldstein FC, Green J, **Green RC**: Anosognosia in Alzheimer's Disease Letter re: Arch Neurol 1995;52:415-420. Archives of Neurology, 53: 10, 1996.
6. McNagny SE, **Green RC**: Commentary "Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease" from Lancet 348:429-432, 1996. ACP Journal Club, p. 21, Jan/Feb, 1997.
7. **Green RC**, Stewart WF: Commentary on "Utility of the Apolipoprotein E genotype in the diagnosis of Alzheimer's disease" by Mayeux et al. from New England Journal of Medicine, 338:506-511, 1998. Neurology Network Commentary, 2:191-196, 1998.

8. Friedland RP, Farrer LF, Cupples LA, et al. Letter responding to “Smoking and risk of Alzheimer’s disease” Lancet, 352:819, 1998.
9. **Green RC**: Book Review of Wimo A et al. (eds) Health Economics of Dementia. The Economics of Neuroscience, in press.
10. **Green RC**: Editorial on “Illness Representations among First-Degree Relatives of People with Alzheimer Disease” by Robert JS, Connel CM. Alzheimer’s Disease and Associated Disorders, 14:127-128, 2000.
11. Brown TC, **Green RC**: Book Review of Post SG and Whitehouse PJ (eds) Genetic Testing for Alzheimer Disease Ethical and Clinical Issues. Amyloid, 8:73-74, 2001.
12. Annas GJ, Roches P, **Green RC**: GINA, Genism and Civil Rights. Bioethics. in press, 2008.

*Books*

1. **Green RC**: Diagnosis and Management of Alzheimer’s Disease and Other Dementias, Professional Communications, Inc., New York, First Edition, 2001; Second Edition, 2005.
2. Read C, **Green RC**, Smyer R (eds): Aging, Genetic Technology and the Future, Johns Hopkins Press, Baltimore, MD, 2008.